Jeraygo (aprocitentan), Idorsia’s first-of-its-kind treatment for resistant hypertension, is among the latest batch of new drugs that the European Medicines Agency today announced should be approved for marketing across the EU.
If approved by the European Commission, Jeraygo will become the EU’s first endothelin receptor antagonist for treating resistant hypertension in adults in combination with at least three antihypertensive medicines, and the first new oral